FBIO - Fortress Biotech, Inc.
IEX Last Trade
1.91
0.100 5.236%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:30:03 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$1.81
0.10
5.52%
Fundamental analysis
9%
Profitability
0%
Dept financing
20%
Liquidity
74%
Performance
0%
Performance
5 Days
5.23%
1 Month
7.74%
3 Months
28.37%
6 Months
7.10%
1 Year
-34.18%
2 Year
249.76%
Key data
Stock price
$1.91
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.44 - $4.43
52 WEEK CHANGE
-$48.29
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Lindsay A. Rosenwald
Region: US
Website: fortressbiotech.com
Employees: 170
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: fortressbiotech.com
Employees: 170
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also develops late stage product candidates such as intravenous Tramadol for the treatment of post-operative acute pain.
Recent news